We are determined to bring the full power of data to the collective fight against cancer.
Through our research and partnerships, we are helping to shape the real-world evidence industry and advance the field of oncology.
Our collaborations are leading industry to advance the treatment landscape, reimagine the drug development life cycle, and accelerate value-based care models.
Discover more about how our work with the FDA, industry and academia helps to ensure that everyone touched by cancer is given a clear path to the right care.
COTA signs a two-year Research Collaboration Agreement (RCA) with the FDA to study variation in cancer treatment patterns using real-world data. This RCA will provide the FDA with information on the evolving breast cancer treatment landscape, including insight on treatment variation.READ MORE
Every pharma company wants to work with startups – for good reason. Startups work with agility to find solutions that often address patients’ unmet needs. As our industry commits to providing more patient value, eyeforpharma is committed to showcasing the brightest and best startups.READ MORE
FDA and COTA recently finalized a research collaboration agreement. Research efforts are underway across tumor types to assess the utility of RWE in drug development for high unmet need populations and in accelerating clinical trials.
Friends of Cancer Research and COTA partnered in a pilot study of immune checkpoint inhibitors approved for non-small cell lung cancer to define a standard data framework and to assess correlation between real-world endpoints and overall survival.
Let’s work together to transform cancer care.CONTACT US